Thyroid disease

PFAS ‘forever chemicals’: Why EPA set federal drinking water limits for these health-harming contaminants

Retrieved on: 
Wednesday, April 10, 2024
Research, GxP, Toxicity, Health, Obesity, PFNA, Liver, Gore-Tex, 3M, PFAS, PFOS, Environment, Name, Risk, Food packaging, Fertility, PFOA, Pregnancy, Life, Diet, Thyroid disease, EPA, Agency, National academy, Water, Kidney, Breast cancer, Scotchgard, Inflammatory bowel disease, Birth weight, Cosmetics, Perfluorohexanesulfonic acid, Vaccine, Soil, Family, Map, Drinking water, Pre-eclampsia, Poison

The U.S. Environmental Protection Agency now believes there is no safe level for two common PFAS – PFOA and PFOS – in drinking water, and it acknowledges that very low concentrations of other PFAS present human health risks.

Key Points: 
  • The U.S. Environmental Protection Agency now believes there is no safe level for two common PFAS – PFOA and PFOS – in drinking water, and it acknowledges that very low concentrations of other PFAS present human health risks.
  • The agency issued the first legally enforceable national drinking water standards for five common types of PFAS chemicals, as well as PFAS mixtures, on April 10, 2024.

What exactly are PFAS?

  • This is a large group of human-made chemicals – currently estimated to be nearly 15,000 individual chemical compounds – that are used widely in consumer products and industry.
  • They can make products resistant to water, grease and stains and protect against fire.
  • The short answer is that PFAS are harmful to human health and the environment.
  • Some of the very same chemical properties that make PFAS attractive in products also mean these chemicals will persist in the environment for generations.
  • The U.S. Geological Survey estimates common types of PFAS are now in at least 45% of the country’s tap water.

What are the health risks from PFAS exposure?

  • Research consistently demonstrates that PFAS are associated with a variety of adverse health effects.
  • A review by a panel of experts looking at research on PFAS toxicity concluded with a high degree of certainty that PFAS contribute to thyroid disease, elevated cholesterol, liver damage, and kidney and testicular cancer.
  • Additionally, current research suggests that babies exposed prenatally are at higher risk of experiencing obesity, early-onset puberty and reduced fertility later in life.
  • Collectively, this is a formidable list of diseases and disorders.

Who’s regulating PFAS?

  • DuPont called it Teflon, which eventually became a household name for its use on nonstick pans.
  • Decades later, in 1998, Scotchgard maker 3M notified the Environmental Protection Agency that a PFAS chemical was showing up in human blood samples.
  • At the time, 3M said low levels of the manufactured chemical had been detected in people’s blood as early as the 1970s.
  • The Agency for Toxic Substances and Disease Registry has a toxicological profile for PFAS.

How can you reduce your PFAS exposure?

  • The best ways to protect yourself and your family from risks associated with PFAS are to educate yourself about potential sources of exposure.
  • Products labeled as water- or stain-resistant have a good chance of containing PFAS.
  • Strategies for monitoring and reporting PFAS contamination vary by location and PFAS source, so the absence of readily available information does not necessarily mean the region is free of PFAS problems.


Kathryn Crawford receives funding from National Institutes of Health and US Geological Survey.

Visionary $15 Million Gift from Wayne & Wendy Holman to NYU Langone Health Ensures Continued Excellence in Newly Named Holman Division of Endocrinology, Diabetes & Metabolism

Retrieved on: 
Wednesday, March 20, 2024
Health, Obesity, Internal medicine, Growth, NYU Langone Health, Caregiver, Physician, Trustee, Metabolism, Education, Patient, Knowledge, Research, Diabetes, NYU, Ridgeback Biotherapeutics, Neuroendocrinology, News, Infection, Thyroid disease, Cancer, Alumni, Medicine, Pharmaceutical industry

NEW YORK, March 20, 2024 /PRNewswire/ -- NYU Langone Health has received a $15 million gift from innovators and philanthropists Wayne G. Holman, MD , and Wendy Holman to further elevate the world-class treatment and study of endocrine disorders in the newly named and endowed Holman Division of Endocrinology, Diabetes & Metabolism.

Key Points: 
  • NEW YORK, March 20, 2024 /PRNewswire/ -- NYU Langone Health has received a $15 million gift from innovators and philanthropists Wayne G. Holman, MD , and Wendy Holman to further elevate the world-class treatment and study of endocrine disorders in the newly named and endowed Holman Division of Endocrinology, Diabetes & Metabolism.
  • "Wayne and Wendy's generosity in this important area of medicine will help NYU Langone further enhance our exceptional research, education and clinical care within the Holman Division of Endocrinology, Diabetes & Metabolism," said Robert I. Grossman, MD , dean and CEO, NYU Langone.
  • "I am excited for the medical advances that will undoubtedly come about because of the Holmans' deep investment."
  • The Holman Division of Endocrinology, Diabetes, & Metabolism, part of the Department of Medicine at NYU Grossman School of Medicine, is among the best in the country, ranked No.

On Feb 6th, Penn Medicine Becker ENT & Allergy Opens a New Location to Increase Access to Quality Care in Woodbury, NJ

Retrieved on: 
Wednesday, February 28, 2024
Allergy, Polyp (medicine), Steam, MD, Immunotherapy, Physician, Quality of life, Medicine, GERD, Probiotic, Ear, Honey, Health, Thyroid disease, ENT, Health care, Instrument, Patient, Disorder, Allergen, Becker, Nose, Veterinary medicine

WOODBURY, N.J., Feb. 28, 2024 /PRNewswire-PRWeb/ -- Expanding Patient Care: Penn Medicine Becker ENT & Allergy's New Woodbury Facility

Key Points: 
  • WOODBURY, N.J., Feb. 28, 2024 /PRNewswire-PRWeb/ -- Expanding Patient Care: Penn Medicine Becker ENT & Allergy's New Woodbury Facility
    The new Penn Medicine Becker ENT & Allergy location in Woodbury is part of their ongoing mission to deliver comprehensive care for ear, nose, throat, and allergy issues to more patients.
  • What the New Penn Medicine Becker ENT & Allergy Location Means for Woodbury, NJ
    The opening of the new Becker ENT location in Woodbury is a major boon for the local community.
  • Penn Medicine Becker ENT & Allergy offers a vast array of ENT and allergy services .
  • Contacting Penn Medicine Becker ENT & Allergy for Care in Woodbury, NJ
    To experience the quality and personalized care that Penn Medicine Becker ENT & Allergy offers, residents of Woodbury, NJ, and surrounding areas can schedule an appointment.

Baird Medical Expands Presence in the United States

Retrieved on: 
Wednesday, February 28, 2024
Interventional radiology, Education, MWA, Physician, FDA, Growth, Weill Cornell Medicine, Annual general meeting, Tulane Medical Center, Safety, Thyroid disease, Society, NYU Langone Health, Patient, Stanford University Medical Center, Pharmaceutical industry

FRISCO, Texas, Feb. 28, 2024 /PRNewswire/ -- Baird Medical Devices, Inc. ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider in China and the United States, today announced that it is accelerating its expansion in the United States through senior hires, key partnerships, and capacity building initiatives to support its business.

Key Points: 
  • FRISCO, Texas, Feb. 28, 2024 /PRNewswire/ -- Baird Medical Devices, Inc. ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider in China and the United States, today announced that it is accelerating its expansion in the United States through senior hires, key partnerships, and capacity building initiatives to support its business.
  • "I am very excited to join Baird Medical at this critical time," said Christian Chilcott, Chief Commercial Officer, Americas, of Baird Medical.
  • Baird Medical offers a rigorous medical education program to build industry capacity and safety as a critical part of its business development.
  • "Entering a mature medical market like the United States requires that we take our time to do it well.

Florida firefighter launches fire-resistant apparel company offering firefighters affordable, hassle-free uniforms

Retrieved on: 
Wednesday, February 21, 2024
Cancer, Woman, Obesity, Fertility, FILO, Risk, Liver, Frustration, Thyroid disease, Firefighter, PFAS, Nomex

JACKSONVILLE, Fla., Feb. 21, 2024 /PRNewswire/ -- Embarking on a personal mission to supply firefighters with safe, convenient, more affordable uniforms, Florida Federal Firefighter/EMT-turned-entrepreneur Sean Conant announced the launch of a new line of fire-resistant clothing: FILO Apparel.

Key Points: 
  • JACKSONVILLE, Fla., Feb. 21, 2024 /PRNewswire/ -- Embarking on a personal mission to supply firefighters with safe, convenient, more affordable uniforms, Florida Federal Firefighter/EMT-turned-entrepreneur Sean Conant announced the launch of a new line of fire-resistant clothing: FILO Apparel .
  • FILO Apparel makes affordable PFAS-free Nomex fire station pants and shirts for firefighters with free shipping.
  • "The company was born out of frustration when shopping for my own uniforms.
  • FILO Apparel uniforms are currently available for purchase at www.filoapparel.com for individual firefighters.

Dr. Raymond Douglas Publishes Prospective Study in Thyroid Medical Journal Examining Audiometry Outcomes Following Tepezza for Thyroid Eye Disease

Retrieved on: 
Tuesday, January 16, 2024
Patient, Research, Teprotumumab, Clutch (eggs), Graves' ophthalmopathy, Health, Multimedia, Thyroid, Hearing loss, Thyroid disease, Quality of life, Pharmacotherapy, FDA, Doctor of Philosophy, Hearing, TED, Medical device

BEVERLY HILLS, Calif., Jan. 16, 2024 /PRNewswire-PRWeb/ -- Raymond Douglas MD, PhD led a new study finding long term hearing loss is rare in those with normal audiometry at baseline following treatment with Tepezza [teprotumumab]. The results also showed with predictability that patients with preexisting hearing issues were those who would potentially develop loss. The study was just published for the current issue of the prestigious journal Thyroid, the definitive peer-reviewed medical journal in thyroid disease, care, and research, providing multidisciplinary original and patient-focused reports.

Key Points: 
  • BEVERLY HILLS, Calif., Jan. 16, 2024 /PRNewswire-PRWeb/ -- Raymond Douglas MD, PhD led a new study finding long term hearing loss is rare in those with normal audiometry at baseline following treatment with Tepezza [teprotumumab].
  • The results also showed with predictability that patients with preexisting hearing issues were those who would potentially develop loss.
  • The study was just published for the current issue of the prestigious journal Thyroid , the definitive peer-reviewed medical journal in thyroid disease, care, and research, providing multidisciplinary original and patient-focused reports.
  • "Our study conclusively confirmed that hearing loss with Tepezza treatment is in fact very rare", said Dr. Raymond Douglas, lead investigator and author.

Development of Prediction Model for Brain Amyloid-Beta Accumulation Using Wristband Sensor

Retrieved on: 
Friday, December 29, 2023
CSF, Alzheimer's Research & Therapy, Alzheimer's disease, Dementia, Learning, Cerebrospinal fluid, Woman, Elastic net regularization, Heart rate, Sleep, Support vector machine, Hypertension, PET, Disease, Diabetes, Thyroid disease, Brain, Ageing, Risk, Stroke, Oita University, Faculty, Speech, Associate professor, Amyloid beta, Biomarker, Machine learning, Future Development, Manuscript, Transport, Patient, Medical school, Cardiovascular disease, MCI, AUC, Social isolation, Eisai, Area, Exercise, Medical imaging

TOKYO, Dec 29, 2023 - (JCN Newswire) - Oita University and Eisai Co., Ltd. (Eisai) hereby announce the development of the world's first machine learning model to predict amyloid beta*1 (Aβ) accumulation in the brain using a wristband sensor.

Key Points: 
  • TOKYO, Dec 29, 2023 - (JCN Newswire) - Oita University and Eisai Co., Ltd. (Eisai) hereby announce the development of the world's first machine learning model to predict amyloid beta*1 (Aβ) accumulation in the brain using a wristband sensor.
  • This model is expected to enable screening for brain Aβ accumulation, which is an important pathological factor of Alzheimer's disease*2 (AD), simply by collecting biological and lifestyle data from daily life.
  • The key to maximizing treatment effects of the medicine is detecting Abeta accumulation in the brain of patients with mild cognitive impairment before the onset of symptoms.
  • This machine learning model is able to predict brain Aβ accumulation using readily available non-invasive variables.

North Star Vascular & Interventional Opens New Center in Minneapolis

Retrieved on: 
Wednesday, December 20, 2023
Technology, FDA, Health, Robotics, Other Health, Radiology, Surgery, Oncology, Practice Management, Medical Devices, Managed Care, General Health, Hospitals, Health Technology, Patient, Google Images, Varicocele, Artery, Pain management, Peripheral artery disease, Risk, Advocate Christ Medical Center, Knee, Physician, Uterine fibroid, Vascular disease, Intervention, Male, Infertility, Kidney disease, Chronic pain, Thyroid disease, Osteoarthritis, MBA, MD, Vein, Cancer, GE HealthCare, University, Moyamoya disease, Neoplasm, Rush University Medical Center, Fibroid, Interventional radiology, Liver cancer, Hospital-acquired infection, Pelvic congestion syndrome, Radiation, Y-90, Medical imaging

The field of vascular and interventional radiology is growing, and three area physicians have opened an outpatient center to provide viable alternatives to hospital-based surgery in Golden Valley.

Key Points: 
  • The field of vascular and interventional radiology is growing, and three area physicians have opened an outpatient center to provide viable alternatives to hospital-based surgery in Golden Valley.
  • North Star Vascular & Interventional (NSVI) offers minimally invasive procedures to treat health conditions such as peripheral artery and venous disease, cancer, enlarged prostate, uterine fibroids and more.
  • Jafar Golzarian, MD, FSIR, professor emeritus of interventional radiology at the University of Minnesota Medical School, has authored more than 400 academic articles and national and international lectures on interventional radiology.
  • Bulent Arslan, MD, FSIR is a Professor of Radiology and Chief of Interventional Radiology at the Rush University Medical Center in Chicago.

Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD

Retrieved on: 
Thursday, November 9, 2023
Group 3, Hepatology, Safety, Immune system, Thyroiditis, RNA interference, AASLD, Risk, MVA, NUC, Patient, HBV, Clinical trial, Non-cirrhotic portal fibrosis, Liver, SOC, Autoimmune thyroiditis, CHB, Cancer, Nivolumab, Hepatitis, Group 2, Autoimmunity, Thyroid disease, Șaeș, Vaccine, Pharmaceutical industry, HBsAg

Alongside this, a late-breaking poster presentation with interim data from patients with chronic hepatitis B (CHB) from the Phase 2a AB-729-202 trial combining Arbutus Biopharma Corporation’s (NASDAQ: ABUS) RNAi therapeutic candidate, imdusiran (AB-729), with Barinthus Bio’s T cell stimulating immunotherapeutic candidate, VTP-300, and SoC NUC therapy.

Key Points: 
  • Alongside this, a late-breaking poster presentation with interim data from patients with chronic hepatitis B (CHB) from the Phase 2a AB-729-202 trial combining Arbutus Biopharma Corporation’s (NASDAQ: ABUS) RNAi therapeutic candidate, imdusiran (AB-729), with Barinthus Bio’s T cell stimulating immunotherapeutic candidate, VTP-300, and SoC NUC therapy.
  • Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.
  • Preliminary immunology data suggests HBV-specific T cell IFN-γ production was enhanced in patients receiving imdusiran plus VTP-300 compared to placebo.
  • Dr. Karen Sims, Chief Medical Officer of Arbutus Biopharma, commented, “Imdusiran consistently delivers compelling efficacy and safety data in multiple Phase 2a populations and combinations.

Baird Medical Attains FDA Clearance to Market Its Microwave Ablation System in the United States

Retrieved on: 
Tuesday, November 21, 2023
Woman, Food, Scar, Incidence, Needle, Patient, FDA, American Thyroid Association, MWA, Thyroid disease, Thyroid nodule, Neoplasm, Procedure, Physician, Breast, Medical imaging

FRISCO, Texas, Nov. 21, 2023 /PRNewswire/ -- Baird Medical Devices, Inc. ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider in China, today announced that its subsidiary, Betters (Suzhou) Medical Co., Ltd, has received clearance from the U.S. Food and Drug Administration (the "FDA") under Section 510 (K) to begin marketing its portfolio of Microwave Ablation Systems and Disposable Microwave Ablation Needles as regulatory Class II devices in the United States.

Key Points: 
  • FRISCO, Texas, Nov. 21, 2023 /PRNewswire/ -- Baird Medical Devices, Inc. ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider in China, today announced that its subsidiary, Betters (Suzhou) Medical Co., Ltd, has received clearance from the U.S. Food and Drug Administration (the "FDA") under Section 510 (K) to begin marketing its portfolio of Microwave Ablation Systems and Disposable Microwave Ablation Needles as regulatory Class II devices in the United States.
  • Ms. Haimei Wu, Founder and CEO of Baird Medical, commented, "Attaining FDA clearance represents a significant milestone in our geographical expansion.
  • This clearance grants us the ability to market our portfolio of MWA systems and disposable needles in the United States.
  • Based on our market research, we estimate that the U.S. presents a market opportunity of $1.6 billion for MWA systems alone.